EXAS
Exact Sciences Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$104.91
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.2B | 3.2B | 2.8B | 2.5B | 2.1B |
| Cost of Revenue | 984.2M | 984.2M | 840.2M | 737.6M | 661.4M |
| Gross Profit | 2.3B | 2.3B | 1.9B | 1.8B | 1.4B |
| Operating Expenses | |||||
| R&D Expense | 523.0M | 523.0M | 431.2M | 426.9M | 394.2M |
| SG&A Expense | 1.9B | 1.9B | 1.7B | 1.6B | 1.6B |
| General & Admin Expense | 888.7M | 888.7M | 1.4B | 1.4B | 663.4M |
| Selling & Marketing Expense | 1.1B | 1.1B | 247.5M | 225.7M | 929.6M |
| Other Expenses | — | (99.9M) | 868.1M | (70.0M) | 29.2M |
| Total Operating Expenses | 2.5B | 2.4B | 3.0B | 2.0B | 2.0B |
| Cost and Expenses | 3.4B | 3.3B | 3.8B | 2.7B | 2.7B |
| Operating Income (EBIT) | (200.4M) | (99.1M) | (1.0B) | (215.0M) | (593.5M) |
| Non-Operating | |||||
| Interest Income | 7.9M | 42.7M | — | — | — |
| Interest Expense | 36.6M | 32.9M | 32.0M | 24.4M | 13.9M |
| Net Interest Income | (28.7M) | 9.9M | (32.0M) | (24.4M) | (13.9M) |
| Other Non-Op Income/Expense | (3.5M) | (104.8M) | 12.5M | 13.3M | (39.1M) |
| Non-Operating Income (excl Interest) | (21.4M) | — | (44.5M) | (37.7M) | 25.2M |
| EBT (Pre-Tax Income) | (203.9M) | (203.9M) | (1.0B) | (201.7M) | (632.6M) |
| Income Tax Expense | 4.1M | 4.1M | (7.3M) | 2.4M | (9.1M) |
| Bottom Line | |||||
| Net Income | (207.9M) | (207.9M) | (1.0B) | (204.1M) | (623.5M) |
| Earnings from Cont. Ops | (207.9M) | (207.9M) | (1.0B) | (204.1M) | (623.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (207.9M) | (207.9M) | (1.0B) | (204.1M) | (623.5M) |
| Per Share | |||||
| Basic EPS | ($1.10) | ($1.10) | ($5.59) | ($1.13) | ($3.54) |
| Diluted EPS | ($1.10) | ($1.10) | ($5.59) | ($1.13) | ($3.54) |
| Revenue Per Share | $17.11 | $17.21 | $14.98 | $13.88 | $11.82 |
| Shares | |||||
| Basic Shares Outstanding | 189.7M | 188.7M | 184.2M | 180.1M | 176.4M |
| Diluted Shares Outstanding | 189.7M | 188.7M | 184.2M | 180.1M | 176.4M |
| Profitability Metrics | |||||
| EBITDA | 42.6M | 122.5M | (789.3M) | 29.3M | (421.1M) |
| D&A | 221.6M | 221.6M | 214.9M | 206.6M | 197.6M |
| EBIT | (179.0M) | (99.1M) | (1.0B) | (177.3M) | (618.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025